These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9099233)

  • 1. Mass spectrometric studies on the inhibition of TEM-2 beta-lactamase by clavulanic acid derivatives.
    Brown RP; Aplin RT; Schofield CJ; Frydrych CH
    J Antibiot (Tokyo); 1997 Feb; 50(2):184-5. PubMed ID: 9099233
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of TEM-2 beta-lactamase from Escherichia coli by clavulanic acid: observation of intermediates by electrospray ionization mass spectrometry.
    Brown RP; Aplin RT; Schofield CJ
    Biochemistry; 1996 Sep; 35(38):12421-32. PubMed ID: 8823177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to beta-lactam antibiotics: structure and mechanism based design of beta-lactamase inhibitors.
    Sandanayaka VP; Prashad AS
    Curr Med Chem; 2002 Jun; 9(12):1145-65. PubMed ID: 12052169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Back mutations to the TEM-1 beta-lactamase from TRC-1 lead to restored sensitivity to clavulanic acid.
    Thomson CJ; Amyes SG
    J Med Microbiol; 1995 Jun; 42(6):429-32. PubMed ID: 7791208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A semi-empirical study of some clavulanic acid derivatives in relation to their activity as beta-lactamase inhibitors.
    Fernández B; Ríos MA
    J Pharm Pharmacol; 1993 Jan; 45(1):25-9. PubMed ID: 8094441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of pH on activities of novel beta-lactamases and beta-lactamase inhibitors against these beta-lactamases.
    Ohsuka S; Arakawa Y; Horii T; Ito H; Ohta M
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1856-8. PubMed ID: 7486932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro pharmacodynamic simulation of clavulanic acid concentrations: effect on Staphylococcus aureus and Haemophilus influenzae beta-lactamase activity.
    Martín M; Aguilar L; Balcabao IP; Gómez-Lus ML; Dal-Ré R; Prieto J
    J Antimicrob Chemother; 1997 Feb; 39(2):290-2. PubMed ID: 9069559
    [No Abstract]   [Full Text] [Related]  

  • 8. Synthesis and beta-lactamase inhibitory activities of some clavulanic acid analogues.
    Mak CP; Prasad K; Turnowsky F
    J Antibiot (Tokyo); 1983 Apr; 36(4):398-406. PubMed ID: 6602120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibacterial activities of amoxicillin alone and in combination with clavulanic acid correlated with beta-lactamase production.
    Hsu LY; Chang SC; Luh KT; Hsieh WC
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1991 Aug; 24(3):272-80. PubMed ID: 1818798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam.
    Piddock LJ; Jin YF; Turner HL
    J Antimicrob Chemother; 1993 Jan; 31(1):89-103. PubMed ID: 8383105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of amikacin and amoxicillin-clavulanic acid against Mycobacterium tuberculosis.
    Tamás F
    Chest; 1993 Jul; 104(1):328. PubMed ID: 8325113
    [No Abstract]   [Full Text] [Related]  

  • 12. The beta-lactamase stability of amoxycillin with the beta-lactamase inhibitor, clavulanic acid.
    Reading C; Farmer T; Cole M
    J Antimicrob Chemother; 1983 Jan; 11(1):27-32. PubMed ID: 6600741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of clavulanic acid, sulbactam and cephamycin antibiotics with beta-lactamases.
    Grace ME; Fu KP; Gregory FJ; Hung PP
    Drugs Exp Clin Res; 1987; 13(3):145-8. PubMed ID: 3040368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro susceptibility of Nocardia asteroides to 21 beta-lactam antibiotics, in combination with three beta-lactamase inhibitors, and its relationship to the beta-lactamase content.
    Kitzis MD; Gutmann L; Acar JF
    J Antimicrob Chemother; 1985 Jan; 15(1):23-30. PubMed ID: 3882654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental application of the median-effect principle for in vitro quantification of the combined inhibitory activities of clavulanic acid and imipenem against IRT-4 beta-lactamase.
    Sotto A; Foulongne V; Sirot D; Labia R; Jourdan J
    Int J Antimicrob Agents; 2002 Jan; 19(1):75-8. PubMed ID: 11814772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A piperacillin-tazobactam resistant Escherichia coli strain isolated from a faecal sample of a healthy volunteer.
    London N; Thomson CJ; Amyes SG; Stobberingh E
    FEMS Immunol Med Microbiol; 1995 Apr; 11(2):107-11. PubMed ID: 7640670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular epidemiology of the plasmid-encoded TEM-1 beta-lactamase in Scotland.
    Thomson CJ; Amyes SG
    Epidemiol Infect; 1993 Feb; 110(1):117-25. PubMed ID: 8432315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raman crystallographic studies of the intermediates formed by Ser130Gly SHV, a beta-lactamase that confers resistance to clinical inhibitors.
    Helfand MS; Taracila MA; Totir MA; Bonomo RA; Buynak JD; van den Akker F; Carey PR
    Biochemistry; 2007 Jul; 46(29):8689-99. PubMed ID: 17595114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transient state kinetic studies on catalysis and inhibition of staphylococcal beta-lactamase.
    Virden R
    J Chemother; 1991 Apr; 3(2):79-82. PubMed ID: 1875236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of beta-lactamase inhibitors in chemotherapy.
    Neu HC
    Pharmacol Ther; 1985; 30(1):1-18. PubMed ID: 3018803
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.